#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ventricular fibrillation Measles Palmar-plantar erythrodysaesthesia syndrome Philadelphia positive acute lymphocytic leukaemia Shprintzen-Goldberg syndrome Synovitis ROHHAD syndrome Prostate cancer Cardiomyopathy Brain stem glioma Dementia Precursor T-lymphoblastic lymphoma/leukaemia recurrent Craniopharyngioma Blood iron increased Dupuytren's contracture More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma recurrent – Trials in Disease Cystic fibrosis lung – Diagnostics Lymphatic malformation – Diagnostics Chondrosarcoma – Treatment Pituitary-dependent Cushing’s syndrome – Life with Disease Splenic marginal zone lymphoma – Diagnostics Rhabdomyosarcoma recurrent Waldenstrom’s macroglobulinaemia Hereditary hypophosphataemic rickets – Diagnostics Usher’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Nanatinostat Sulfamethizole Ruzasvir Elebsiran Rocatinlimab Ropeginterferon Alfa-2B Opevesostat ACARBOSE Doxazosin Tocotrienol Samuraciclib Db-1303 Ganaxolone Ferric Derisomaltose Tovinontrine Adrc001 Quinapril Hydrochloride Fusidic Acid Ly3556050 Palonosetron More therapies…

    Learn about Your Condition

    Lichen planus Glanzmann's disease Arterial stiffness Decreased appetite Coronary artery dissection Heart disease congenital Malignant oligodendroglioma Adenocarcinoma of colon Multifocal motor neuropathy Carotid artery occlusion Congenital pseudarthrosis Lymphangiosarcoma Diminished ovarian reserve Arteriospasm coronary Extraskeletal ossification More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Vemurafenib
    Czechia France Germany Greece Hungary Italy +4

  • Study of Lower Dose Olaparib Combined with Cobicistat to Improve Treatment Tolerance in Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Cobicistat
    The Netherlands

  • Study on Atezolizumab, Amivantamab, and Futibatinib for Patients with Advanced Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Futibatinib
    • Amivantamab
    • Atezolizumab
    France Germany Italy The Netherlands Spain Sweden

  • Study on Heart Function Changes in Cancer Patients Treated with Nivolumab or Pembrolizumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Nivolumab
    • Pembrolizumab
    France

  • Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile – FINPROVE Study

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Dabrafenib
    • Pemigatinib
    • Tepotinib
    Finland

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Lymphoma
    • Squamous cell carcinoma of lung
    • Neoplasm malignant
    Investigated Drugs:
    • Imsidolimab
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Mps-102
    Belgium France Spain
Previous Page
1 … 3 4 5 6 7 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!